Milos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insider Milos Miljkovic sold 932 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $16.72, for a total transaction of $15,583.04. Following the sale, the insider now directly owns 36,341 shares of the company’s stock, valued at $607,621.52. This represents a 2.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Milos Miljkovic also recently made the following trade(s):

• On Monday, January 6th, Milos Miljkovic sold 948 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.83, for a total transaction of $15,954.84.
• On Thursday, November 14th, Milos Miljkovic sold 35,000 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.13, for a total transaction of $564,550.00.

Cartesian Therapeutics Trading Down 2.7 %

Shares of Cartesian Therapeutics stock traded down $0.47 during trading hours on Tuesday, hitting $17.16. 105,686 shares of the company were exchanged, compared to its average volume of 132,021. The stock has a market capitalization of $436.12 million, a price-to-earnings ratio of -0.32 and a beta of 0.56. The business has a 50-day moving average of $19.32 and a 200-day moving average of $18.19. Cartesian Therapeutics, Inc. has a 1 year low of $11.66 and a 1 year high of $41.87.

Analyst Ratings Changes

Several brokerages recently weighed in on RNAC. Cantor Fitzgerald upgraded Cartesian Therapeutics to a “hold” rating in a research report on Monday, December 2nd. BTIG Research assumed coverage on Cartesian Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $42.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $45.00 target price (up previously from $41.00) on shares of Cartesian Therapeutics in a research note on Wednesday, December 4th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 target price on shares of Cartesian Therapeutics in a research note on Tuesday, December 3rd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.86.

Institutional Trading of Cartesian Therapeutics

A number of institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in shares of Cartesian Therapeutics by 0.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 309,018 shares of the company’s stock worth $4,981,000 after acquiring an additional 2,688 shares in the last quarter. Barclays PLC increased its stake in shares of Cartesian Therapeutics by 208.6% during the 3rd quarter. Barclays PLC now owns 11,611 shares of the company’s stock worth $188,000 after purchasing an additional 7,849 shares in the last quarter. Geode Capital Management LLC grew its holdings in Cartesian Therapeutics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 135,700 shares of the company’s stock valued at $2,188,000 after buying an additional 2,737 shares during the last quarter. State Street Corp boosted its stake in shares of Cartesian Therapeutics by 2.5% during the 3rd quarter. State Street Corp now owns 157,495 shares of the company’s stock worth $2,539,000 after purchasing an additional 3,830 shares during the last quarter. Finally, Great Point Partners LLC acquired a new position in shares of Cartesian Therapeutics in the third quarter valued at approximately $3,224,000. 86.95% of the stock is currently owned by hedge funds and other institutional investors.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.